
Please try another search
Name | Net % | Long % | Short % |
---|---|---|---|
Cash | 11.000 | 11.000 | 0.000 |
Shares | 94.080 | 94.080 | 0.000 |
Ratios | Value | Category Average |
---|---|---|
P/E Ratio | 41.445 | 22.347 |
Price to Book | 3.196 | 2.714 |
Price to Sales | 5.120 | 3.330 |
Price to Cash Flow | 25.014 | 16.400 |
Dividend Yield | 0.156 | 2.102 |
5 Years Earnings Growth | 4.010 | 6.822 |
Name | Net % | Category Average |
---|---|---|
Healthcare | 99.970 | 97.797 |
Basic Materials | 0.010 | 0.472 |
Industrials | 0.010 | 0.563 |
Technology | 0.010 | 0.380 |
Number of long holdings: 91
Number of short holdings: 1
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
BeOne Medicines | CNE100005XT6 | 9.58 | 224.63 | -4.68% | |
Jiangsu Hengrui | CNE0000014W7 | 9.10 | 60.99 | +0.30% | |
InnoCare Pharma | CNE100005P56 | 9.04 | 28.58 | -2.59% | |
Dizal Jiangsu Pharmaceutical | CNE1000055W8 | 7.04 | 73.00 | -1.20% | |
Shouyao Holdings Beijing | CNE1000062V6 | 6.32 | 46.25 | -2.01% | |
Sichuan Biokin Pharmaceutical | CNE100006FN4 | 5.84 | 295.45 | -0.99% | |
Gan Lee Pharmaceuticals | CNE100003ZH1 | 5.61 | 61.48 | -1.57% | |
RemeGen | CNE100005B03 | 5.51 | 62.60 | +1.28% | |
Suzhou Zelgen Biopharma | CNE100003RP1 | 5.00 | 106.20 | -3.24% | |
Hinova Pharmaceuticals | CNE1000059F5 | 4.52 | 54.97 | -1.84% |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Penghua HK Bank Index LOF | 7.38B | 23.93 | 19.90 | - | ||
Penghua Jiangxin Sele Alloc C | 6.94B | 3.82 | -4.15 | - | ||
Penghua CSI Guofang Idx Classified | 4.15B | 17.64 | -5.73 | -3.59 | ||
Penghua HongKang mix A | 3.55B | 0.68 | 2.42 | - | ||
Penghua HongKang mix C | 3.55B | 0.61 | 2.31 | - |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review